Our News
HMRI, Titan and Medtronic unite to deliver pioneering stroke clinical trial
Hunter Medical Research Institute (HMRI) forms international partnership with Titan Neuroscience and Medtronic to spearhead the FRONTIER AP clinical trial. HMRI will be the Academic Research Organisation (ARO) and Sponsor for the Melbourne-based clinical trial, which aims to test a new treatment for acute ischaemic stroke called Endovascular Clot Retrieval or thrombectomy.  This new treatment has proven effective in removing clots from large vessels in people who have had a stroke. This Phase 2 trial now aims to assess its applicability in medium vessels, potentially unlocking new dimensions in stroke treatment.

HMRI Chief Partnership and Development Officer, Todd Williams, is enthusiastic about the partnership and the opportunity to deliver an end-to-end clinical trial solution.

“HMRI prides itself on delivering innovative and scalable health and medical solutions. Our whole reason for existing is to transform the health and wellbeing of our communities and this is just another way we are partnering with industry to advance health outcomes, while also shoring up the financial future of medical research in the Hunter,” says Williams.

“HMRI’s partnership with Hunter New England Local Health District, University of Newcastle and the Primary Health Network enables us to deliver and lead world-class clinical trials. Our ecosystem is built and designed to lead clinical trials just like this one.” Leveraging a confidential technology from global MedTech leader, Medtronic, the clinical trial promises to expand horizons in stroke treatment and recovery. Titan Neuroscience Research, a leading healthcare research company based in Melbourne, will conduct the clinical trial.  

Professor Mark Parsons, a world-leading stroke neurologist and Co-Founder of Titan, says, “This program highlights the immense potential of Australian industry and medical research partnerships to drive technology innovation in the clinical trial space. This is just the first step in what we hope will be a fruitful, long-term partnership with HMRI.” The Phase 2 trial seeks to recruit 240 adult patients presenting with acute ischaemic stroke within nine hours of stroke onset. The trial commenced in January 2024 and is expected to take around five years, running nationally and internationally across comprehensive stroke centres in Australia and the Asia Pacific.

Original source:
Titan and Nicolab sign MOU for Collaborative Partnership
Members of Nicolab and Titan smiling for a group photo. Underneath the photo are the company logos and logos for Zeus and Strokeviewer.
Photo L-R: Nico Klay (Nicolab Board Director), Renan Sales-Barros (Nicolab CTO), A/Prof Andrew Bivard (Titan CTO), Prof Mark Parsons (Titan Director), Jess Adams (Nicolab COO), Michael Macilquham (Nicolab CCO), Adi Inbar (Nicolab Alliance Manager), Philip Bos (Nicolab CCSO)

MELBOURNE, AUSTRALIA - Nicolab, a publicly unlisted Australian-based company, and Titan Neuroscience Research Australia, a Melbourne-based health technology R&D firm, are pleased to announce the formal signing of a Memorandum of Understanding (MOU) between the two organisations. The MOU outlines the establishment of a collaborative partnership aimed at leveraging their respective resources and expertise, bringing together unique telehealth and brain imaging capabilities to enable exceptional prehospital care for stroke patients.
This MOU signifies the unwavering commitment of both organisations to revolutionise pre-hospital workflow through the implementation of an AI-driven clinical decision support and workflow solution. The primary focus of this partnership will initially be directed towards enhancing acute stroke services.  Nicolab specialises in cutting-edge technology for digital telehealth services, particularly in stroke diagnosis and triage, exemplified by their world-renowned StrokeViewer product. Titan is a leading healthcare research company that specialises in delivering digital health technologies and AI-powered clinical decision assistance technologies. Its digital telestroke platform, Zeus, integrates essential features such as online clinical forms, patient geo-tracking, direct ambulance-to-neurologist communication, and enables rapid triage for stroke patients.

Bringing together Nicolab's StrokeViewer solution and Titan's Zeus solution sets the foundation for a revolutionary approach to diagnosing, assessing, and treating stroke and other acute diseases. By combining their efforts, the two companies aim to equip healthcare professionals with an innovative tool that empowers them to make faster, more accurate decisions, ultimately saving lives and reducing long-term disabilities. Regional and remote Australians are 17% more likely to experience a stroke, and patients who are diagnosed and treated as quickly as possible have a greater chance of recovery. It is anticipated that the technology and expertise developed from this partnership will particularly benefit regional, remote and Indigenous Australians.  "We are thrilled to embark on this transformative journey. Together, we share a vision of how our disruptive technology will shape the future of healthcare and revolutionise pre-hospital workflow," stated Michael Macilquham, Chief Commercial Officer at Nicolab. 

Prof Mark Parsons, a world-leading stroke neurologist and Co-Founder of Titan, expressed his enthusiasm for the collaboration: "This development highlights the immense potential of Australian industry and medical research partnerships to drive technology innovation in the prehospital space. Early in 2023 we were pleased to see that Zeus had delivered a positive impact for acute stroke care in South Australia. We are excited to be exploring how StrokeViewer and Zeus can further transform acute care for stroke patients and optimise health service delivery more broadly.”

StrokeViewer incorporates deep learning algorithms that analyse computed tomography (CT) scans to identify and quantify critical stroke-related parameters. By automating the detection and segmentation of ischaemic regions, StrokeViewer empowers physicians to make faster and more accurate treatment decisions, ultimately leading to improved patient outcomes.

About Nicolab
Nicolab’s vision is to empower healthcare professionals with quick and reliable access to information when it matters most. By providing physicians with all necessary information at their fingertips, they can diagnose patients more accurately and make faster treatment decisions. Nicolab’s algorithms analyse and aggregate complex medical imaging data into an easy to use workflow to streamline acute clinical care.

Website: https://www.nicolab.com/
LinkedIn: https://www.linkedin.com/company/nico-lab 

About Titan Neuroscience Australia
Titan Neuroscience Australia’s mission is to transform prehospital care. Bringing together leaders in clinical research and implementation, Titan equips paramedics with new digital tools and advanced training to enhance their clinical workflows.  Titan’s unique multidisciplinary expertise, data analytics platforms and clinical trials network helps health partners expedite clinical implementation of new technologies and models of care.

Website: https://www.titanneuro.com/
LinkedIn: https://www.linkedin.com/company/titan-neuroscience-research-australia/

For further information please contact:
Titan Neuroscience Research Australia
Brett Drummond
Communications Lead
0439 636 279 

Kylie Westren
Country Manager, ANZ
0482 036 457